Telehealth

Search documents
Berger Montague PC Investigating Claims on Behalf of LifeMD, Inc. (NASDAQ: LFMD) Investors After Class Action Filing
Prnewswire· 2025-08-28 22:51
Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and failing to account for rising customer acquisition costs, leading to a significant drop in share value [1][3]. Company Overview - LifeMD, Inc. is a direct-to-consumer telehealth company based in New York, providing virtual healthcare services and pharmacy offerings in areas such as men's health, obesity treatment, and chronic care [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025, with a deadline of October 27, 2025, for investors to seek lead plaintiff status [1][2]. - The complaint claims that LifeMD raised its 2025 guidance recklessly, which contributed to the misrepresentation of its financial health [3]. Financial Impact - Following the revelation of the company's financial issues, LifeMD shares experienced a dramatic decline, losing 44% of their value in a single trading session [3].
Teladoc: A Telehealth Titan in Trouble?
The Motley Fool· 2025-08-25 23:00
Group 1 - Teladoc's stock has experienced a significant decline, raising questions about its potential for recovery [1] - The analysis includes insights from expert analysts regarding Teladoc's performance and future prospects [1] - The video analysis was published on August 25, 2025, providing timely information on market trends and investment opportunities [1] Group 2 - Anand Chokkavelu, CFA, and Travis Hoium hold positions in Teladoc Health, indicating a level of confidence in the company's future [2] - Rick Munarriz does not hold any positions in the mentioned stocks, suggesting a more cautious approach [2] - The Motley Fool has positions in and recommends Teladoc Health, reflecting a positive outlook from the organization [2]
Hydreight Achieves 33% YoY H1 Revenue Growth, Records 3rd Consecutive Quarter of Profitability, and Strengthens Performance Across Verticals
Globenewswire· 2025-08-25 22:38
“We had a great first 6 months, with 33% year-over-year growth. We have also exceeded our internal metrics across all verticals in the first seven months of the year, reinforcing the strength of our strategy. A key focus has been our investment in making the VSDHOne platform fully modular, allowing customers to adopt it module by module to fit their needs. At the same time, we’ve been prioritizing acquisitions and strategic investments that strengthen our margins, accelerate growth, and expand our ecosystem ...
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire
Benzinga· 2025-08-25 18:26
Core Viewpoint - The most shorted stocks on Wall Street, including Rocket Companies Inc, Oscar Health Inc, and Hims & Hers Health Inc, are positioned precariously, with significant short interest indicating potential for volatility and short squeezes [1][2][6]. Group 1: Company Performance - Rocket Companies has seen a remarkable increase of over 75% year-to-date, with a market capitalization nearing $40 billion and 37% of its shares sold short [3]. - Oscar Health has rebounded with a 25% increase this year, maintaining a short interest just under 30% and only 1.5 days to cover, indicating a potential for a quick squeeze [4]. - Hims & Hers has experienced a staggering 170% rise over the past year, although it has recently pulled back nearly 25%. It has a market cap of $9.7 billion and 35% of its float remains shorted, making it a high-risk short position [5]. Group 2: Market Dynamics - The current market environment is characterized by high short interest ratios and thin days to cover, suggesting that Rocket, Oscar, and Hims could transition from being heavily shorted to experiencing significant upward momentum if retail traders engage [2][6]. - The presence of retail traders looking for the next potential squeeze adds to the volatility of these stocks, making them susceptible to rapid price changes [2][6].
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS
GlobeNewswire News Room· 2025-08-23 13:45
Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged securities fraud related to misleading statements about its collaboration with Novo Nordisk and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations of the Lawsuit - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - It is alleged that the company failed to disclose the risks associated with its collaboration with Novo Nordisk, leading to a significant risk of termination of the partnership [2] - Novo Nordisk officially terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason, resulting in a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5] - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [5]
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeMD, Inc. - LFMD
GlobeNewswire News Room· 2025-08-21 17:55
Core Viewpoint - LifeMD, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and increased customer acquisition costs [1][3]. Financial Performance - On August 5, 2025, LifeMD reported its second quarter 2025 results, indicating that customer acquisition costs rose by 5% to 25% compared to the previous quarter, impacting the business negatively [3]. - The company's transition into the weight management space was highlighted as a significant factor in the increased costs, with analysts suggesting that management lost focus on customer acquisition for its RexMD platform [3]. Stock Market Reaction - Following the announcement of the second quarter results, LifeMD's stock price experienced a significant decline, falling by $5.31 per share, or 44.84%, closing at $6.53 per share on August 6, 2025 [4].
The Gross Law Firm Notifies Hims & Hers Health, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HIMS
Prnewswire· 2025-08-21 12:45
Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims & Hers Health, Inc. spans from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements made by the defendants about the company's business and operations lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].
INVESTOR DEADLINE MONDAY: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS
Prnewswire· 2025-08-21 12:00
CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over- the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform." The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleadin ...
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS
GlobeNewswire News Room· 2025-08-20 15:40
Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2] - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, due to these deceptive practices, leading to a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 [5]
Here's How I Am Buying Hims & Hers At $37 Or Earning 4.2% Monthly Instead
Seeking Alpha· 2025-08-20 08:49
Core Viewpoint - Hims & Hers (NYSE: HIMS) is considered one of the most undervalued growth stories in the telehealth sector, with a reported Q2 revenue of $545 million, reflecting a 73% year-over-year increase, positioning the company for an annual revenue of $2.4 billion [1] Company Summary - Hims & Hers reported Q2 revenue of $545 million, which is a 73% increase compared to the previous year [1] - The company is on track to achieve an annual revenue of $2.4 billion [1] Industry Context - The telehealth industry is experiencing significant growth, with companies like Hims & Hers leading the way in terms of revenue increases and market potential [1]